Does a biotech or life sciences startup need a business owners policy (BOP), and what does it actually cover?

A BOP is worth having early. It packages the two coverages every business needs - general liability (third-party bodily injury and property damage) and commercial property (your equipment, tenant improvements, and contents) - often with business interruption, at a bundled small-business price. It typically satisfies the certificate-of-insurance requirement in an office or lab lease, which is usually the first insurance a startup is actually forced to buy.

What a BOP is not is a life-sciences program. The exposures that make life sciences distinct sit outside a BOP entirely, so a company that stops at a BOP is uninsured for the claims most likely to threaten it.

General liability: third-party bodily injury and property damage arising from ordinary operations - a visitor injured at the office, damage to a landlord's property. Usually written at $1M per occurrence / $2M aggregate, the limits most leases and vendor contracts require.

Commercial property: the company's physical assets - lab equipment, benches, computers, furniture, tenant improvements - against fire, theft, and similar perils, up to the scheduled value. For a lab, confirming that specialized equipment is scheduled at proper replacement value matters.

Business interruption: lost income and continuing expenses if a covered property loss shuts operations down. Useful, but note it responds to physical-damage events, not to a clinical hold, a failed readout, or a supply disruption.

Products liability / completed operations: once a biotech has a product in humans or in the market, product injury is the central exposure - and while general liability nominally includes products/completed operations, generic BOP forms frequently sub-limit or exclude it, and life-sciences product risk needs dedicated products liability underwritten by a market that understands it.

Professional liability (E&O): claims that a service or professional judgment caused harm - central for any company providing research, testing, or advisory services. Not in a BOP.

Directors and officers (D&O): management-decision claims, required by investors at the first institutional round. Not in a BOP.

Clinical trial liability: subject injury in human studies, required by protocols, IRBs, and sponsor agreements. Not in a BOP.

Cyber liability: breach of research data, subject PHI, or proprietary information. Not in a BOP.

A BOP is the appropriate primary policy for an early, pre-clinical company: a small team, an office or lab lease to satisfy, no product in humans, no outside institutional capital, no service being sold to third parties. At that stage the BOP plus workers compensation is a reasonable complete picture.

The company outgrows the BOP-only posture at identifiable triggers: taking institutional capital (add D&O), enrolling human subjects (add clinical trial liability), putting a product into humans or the market (add dedicated products liability), selling a service (add E&O), or holding sensitive data (add cyber - effectively day one for most). Each trigger adds a line the BOP does not contain; the BOP itself remains the general-liability-and-property floor underneath them.

A BOP for a small life-sciences company commonly runs in the low-to-mid four figures annually, driven by property values, square footage, lab vs office use, and location. It is inexpensive relative to what it covers, which is part of why it is a sensible floor.

Some carriers will endorse EPLI or a small cyber sub-limit onto a BOP, which can be convenient at the earliest stage. As the company adds D&O, E&O, products, and clinical trial coverage, those lines are usually better placed in dedicated policies or a management-liability program than stretched onto the BOP. The BOP stays as the underlying general-liability and property layer while the specialty tower is built on top.